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Abstract
Background: Foamy viruses (FVs) unlike orthoretroviruses express Pol as a separate precursor protein and not as a
Gag-Pol fusion protein. A unique packaging strategy, involving recognition of briding viral RNA by both Pol
precursor and Gag as well as potential Gag-Pol protein interactions, ensures Pol particle encapsidation.
Results: Several Prototype FV (PFV) Gag-Pol fusion protein constructs were generated to examine whether PFV
replication is compatible with an orthoretroviral-like Pol expression. During their analysis, non-particle-associated
secreted Pol precursor protein was discovered in extracellular wild type PFV particle preparations of different origin,
copurifying in simple virion enrichment protocols. Different analysis methods suggest that extracellular wild type PFV
particles contain predominantly mature p85
PR-RT and p40
IN Pol subunits. Characterization of various PFV Gag-Pol fusion
constructs revealed that PFV Pol expression in an orthoretroviral manner is compatible with PFV replication as long as a
proteolytic processing between Gag and Pol proteins is possible. PFV Gag-Pol translation by a HIV-1 like ribosomal
frameshift signal resulted in production of replication-competent virions, although cell- and particle-associated Pol
levels were reduced in comparison to wild type. In-frame fusion of PFV Gag and Pol ORFs led to increased cellular Pol
levels, but particle incorporation was only marginally elevated. Unlike that reported for similar orthoretroviral constructs,
a full-length in-frame PFV Gag-Pol fusion construct showed wildtype-like particle release and infectivity characteristics. In
contrast, in-frame PFV Gag-Pol fusion with C-terminal Gag ORF truncations or non-removable Gag peptide addition to
Pol displayed wildtype particle release, but reduced particle infectivity. PFV Gag-Pol precursor fusion proteins with
inactivated protease were highly deficient in regular particle release, although coexpression of p71
Gag resulted in a
significant copackaging of these proteins.
Conclusions: Non-particle associated PFV Pol appears to be naturally released from infected cells by a yet
unknown mechanism. The absence of particle-associated Pol precursor suggests its rapid processing upon particle
incorporation. Analysis of different PFV Gag-Pol fusion constructs demonstrates that orthoretroviral-like Pol
expression is compatible with FV replication in principal as long as fusion protein processing is possible.
Furthermore, unlike orthoretroviruses, PFV particle release and infectivity tolerate larger differences in relative
cellular Gag/Pol levels.
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Background
Spuma- or foamy viruses (FVs) are a special type of retro-
viruses that have adopted features in their replication
strategy commonly found in both orthoretrovirinae and
hepadnaviridae [reviewed in [1]]. In respect to their
expression strategy for the overlapping viral capsid (Gag)
and polymerase (Pol) open reading frames (ORFs), FVs
do not follow the standard orthoretroviral transcription
and translation mechanism, which includes Gag- and
Gag-Pol fusion protein precursor expression from the
same mRNA.
Orthoretroviruses express Pol exclusively as Gag-Pol
fusion proteins from their full-length genomic RNA by
ribosomal frameshift or termination read-through
mechanisms [reviewed in [2]]. In human immunodefi-
ciency virus (HIV), ribosomal frameshifting occurs at a
frequency of 5-10% and involves two structural elements,
a slippery heptamer at which the translating ribosome
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secondary stem-loop structure as stimulator of ribosomal
frameshifting 3’ to the slippery sequence [3]. Retroviral
ribosomal frameshifting or termination read-through not
only permit Pol precursor synthesis, but also are essential
for maintenance of the specific ratio of Gag-Pol to Gag
precursor proteins. For orthoretroviruses an adequate
ratio of these two precursor proteins is critical for capsid
assembly, infectivity, and incorporation of the viral RNA
genome [4-8]. It is generally believed that orthoretroviral
Gag-Pol is incorporated into the virion via interactions
with the Gag precursor, although particle association of
Pol has been reported for murine leukemia virus (MLV)
and HIV, when artificially expressed as a separate protein
[9,10]. Orthoretroviral Gag-Pol copackaging is dependent
on both the major homology region and adjacent C-
terminal capsid sequences that are present in both pro-
teins. The Gag-Pol precursor itself is unable to correctly
assemble into infectious orthoretroviral particles.
FVs express Pol independently of Gag as a separate
precursor protein that is translated from a singly spliced
subgenomic mRNA [reviewed in [11]]. FVs seem to regu-
late the relative cellular expression levels of Gag and Pol
b yt h eu s eo fas u b o p t i m a lP o ls p l i c es i t e[ 1 2 ] .A sac o n -
sequence to this unusual Pol biosynthesis FVs have
developed a special strategy to ensure Pol particle incor-
poration, essential for generation of infectious virions.
Both Gag and Pol precursor proteins of FVs bind to full-
length genomic viral transcripts [13,14]. Additionally pro-
tein-protein interactions between Gag and Pol seem to be
involved in this assembly process as well [15]. Further-
more, only the PFV Pol precursor p127
Pol and not its
mature processing products p85
PR-RT and p40
IN are
incorporated into virions that preassemble their capsids
intracellularly, close to the centrosome in a B/D type
fashion [13,16].
PFV RNA genome and Pol precursor protein packaging
into capsid structures requires at least two cis-acting
sequences (CASI and CASII) [reviewed in [17]]. These
elements comprise the 5’ UTR of the FV RNA genome
including a 5’ part of the Gag ORF (CASI, nt 1-645) as
well as discontinuous regions within a 2 kb fragment of
the 3’ part of the Pol ORF (CASII, nt 3869-5884). Within
these two CAS elements, regions essential for RNA and/
or Pol encapsidation as well as PR activity have been
characterized [13,14,18].
Here, we examined whether PFV replication is compati-
ble with an orthoretroviral-like Gag-Pol expression. Differ-
ent artificial PFV Gag-Pol fusion constructs, including
in-frame fusions and ribosomal frameshift mediated
fusions, were generated. They were characterized in a
proviral as well as in a replication-deficient vector system
context to examine the effects of orthoretroviral-like
PFV Gag-Pol fusion protein expression on virion
morphogenesis, release, and infectivity. In particular, we
were interested in determining whether, similar to orthor-
etroviruses, the ratio of FV Gag to Gag-Pol fusion proteins
is very critical for particle morphogenesis. Furthermore,
we determined whether unprocessed PFV Gag-Pol fusion
proteins alone support capsid assembly and release.
Results
Release of non-particle associated PFV Pol protein
During the course of this study we observed, in some
control samples, the release of PFV Pol precursor pro-
tein p127
Pol into the cell culture supernatant when Pol
was expressed alone after transient transfection of 293T
cells (Figure 1A, lane 8). This apparently non-particle-
associated Pol precursor protein was pelleted through
20% sucrose in a similar fashion as particle-associated
Pol proteins and other viral structural proteins. A major
difference was the absence of Pol cleavage products
p85
PR-RT and p40
IN in supernatant pellets when Pol was
expressed alone, whereas both processing products were
present in the corresponding cell lysates (Figure 1A,
lane 8, 14). In addition, this extracellular Pol precursor
appeared to be present as free protein and not in a lipid
membrane enveloped vesicular form because it was
completely sensitive to subtilisin digestion (Figure 1A,
lane 7, 8). This suggested that the PFV Pol precursor
protein, but not its processing products, is released into
the supernatant by non-conventional secretion mechan-
isms as it lacks a classical signal peptide sequence [19].
Pol precursor protein is frequently detected in PFV
particle preparations of different origin [13,16,20,21]. To
examine whether this really reflects not yet or incomple-
tely processed particle-associated precursor protein or
alternatively copurified extraparticular p127
Pol, we gener-
ated wild type PFV particle preparations originating from
various sources. Viral supernatants were obtained either
by transient transfection of replication-deficient vector
constructs and proviral expression vectors in 293T cells
or alternatively from infected BHK/LTR(PFV)lacZ cul-
tures. Subsequently, particles were concentrated by ultra-
centrifugation through 20% sucrose and duplicate
samples were digested either with subtilisin or mock
incubated. The analysis of the protein composition of
these samples revealed that the majority of p127
Pol pre-
cursor present in these different particle preparations
was sensitive to subtilisin digestion and therefore most
probably was not particle-associated (Figure 1A, lane
1-6). In contrast, the Pol processing product p40
IN was
resistant to subtilisin digestion whereas, in some experi-
ments, a limited subtilisin sensitivity of the p85
PR-RT sub-
unit was observed. PFV Gag p71
Gag and p68
Gag proteins
were always insensitive to subtilisin digestion (Figure 1A,
lane 1-6). Furthermore, as expected, the extracellular Env
subunit gp80
SU was completely digested by subtilisin
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Figure 1 Analysis of PFV Pol particle association in virus samples of different origin. A) Western blot analysis of viral particle preparations of
different origin, concentrated by ultracentrifugation through 20% sucrose and digested by subtilisin (+) or mock incubated (-) prior to lysis, using
antibodies specific for PFV p85
PR-RTand PFV p40
IN (a-RT + a-IN), PFV Gag (a-Gag), PFV Env LP (a-LP), PFV Env SU (a-SU), or mouse GAPDH (a-
GAPDH) as indicated. Cell culture supernatants (30 ml total) were harvested after transient transfection of 293T cells (six 10 cm dishes per sample)
with 16 μg wild type proviral expression construct pczHSRV2 wt (provirus transf., lane 3+4 [15 ml sup], lane 12 [1/30 10 cm dish]), transient co-
transfection with 4-plasmids for a replication-deficient PFV vector system (4 μg puc2MD9, 4 μg p6iGag4, 4 μg p6iPol, 4 μg pczHFVenv EM002) (4-
component, lane 5+6 [15 ml sup], lane 13 [1/30 10 cm dish]), transient transfection with the Pol expression construct p6iPol (4 μg+1 2μg pUC19)
alone (Pol, lane 7+8 [15 ml sup], lane 14 [1/30 of a 10 cm dish]), or from infected BHK/LTR(HFV)lacZ cells (provirus inf., lane 1+2 [11 ml d9 MOI 1
infection sup], lane 11 [1/8 of a 175 cm
2 flask]). B-F) Linear velocity sedimentation gradient centrifugation analysis of PFV particles generated by
transient transfection of 293T cells with the wild type proviral expression construct pczHSRV2 wt (forty-two 10 cm dishes, 210 ml supernatant total),
concentrated by ultracentrifugation through 20% sucrose and prior pretreatment either by subtilisin digestion (+Sub, 60 ml supernatant
equivalents), with 1% NP40 (+NP40, 90 ml supernatant equivalents), or mock incubated (mock, 60 ml supernatant equivalents). B) Infectious titer
and density of the individual fractions from top to bottom (1-16). C-F) Western blot analysis of the load (lane 1, 1/12 of total) and the individual
fractions F1-F16 (lane 2-17, 3/4 of total) using C) monoclonal antibodies specific for PFV Pol p85
PR-RT and p40
IN subunits (a-RT + a-IN), D) polyclonal
antibodies specific for PFV Gag (a-Gag), E) monoclonal antibodies specific for PFV Env SU (a-SU), and F) polyclonal antibodies specific for PFV Env
LP (a-LP). Subtilisin protein crossreacting with the PFV Env LP antiserum is marked with an asteriks. L: load.
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LP
removed only its extracellular C-terminal domain result-
ing in a protein with lower molecular weight (Figure 1A,
lane 1-6).
To further support these observations, PFV particle pre-
parations, concentrated by ultracentrifugation through
20% sucrose and pretreated with detergent, subtilisin or
mock incubated, were separated by linear velocity gradient
centrifugation on iodixanol gradients. Subsequently, the
viral protein composition and infectivity of the individual
gradient fractions were determined by Western blot analy-
sis and titration on appropriate indicator cells, respectively.
The result of such an analysis for replication-competent
virus particle preparations generated by transient transfec-
tion of 293T cells with a PFV proviral expression construct
is shown in Figure 1B-F.
Mock treated supernatants fraction 7 to 9, with densities
of 1.10 to 1.13 g/ml, harbored the highest infectious virus
loads (Figure 1B, fractions 7-9) and coincided with the
strongest protein signals for Gag and Env (Figure 1D-F,
fractions 7-9 upper panels). For Pol proteins the result was
different. The highest amounts of Pol processing products
p85
PR-RT and p40
IN were in accordance with the fraction
infectivities (Figure 1C, upper panel). In contrast, a shift
toward higher density fractions associated with lower
infectivities was observed for the amount of p127
Pol
precursor protein present in these particle preparations
(Figure 1C, upper panel). Subtilisin digestion of concen-
trated particles prior to velocity gradient centrifugation led
to a shift of the major PFV particle containing fractions
(fractions 5-8) to a lower density and the complete
removal of gp80
SU and p127
Pol but not the mature p85
PR-
RT and p40
IN Pol subunits (Figure 1C-E, middle panels).
The lower density of the subtilisin-digested PFV particles
probably reflects the removal of the extracellular domains
of the envelope subunits. NP40 treatment of virions prior
and during velocity gradient centrifugation resulted in a
shift of the major Gag and Pol protein containing fractions
toward higher densities, probably representing membrane
stripped PFV capsids (Figure 1C-D, lower panels). Further-
more, an overall broader density distribution of these pro-
teins compared to untreated samples was observed, which
might be an indication for an increased rate of disassembly
of naked capsids (Figure 1C-D, lower panels). However, by
this treatment no clear separation of Pol precursor and its
cleavage products was observed (Figure 1C, lower panel).
In contrast, Env subunits were physically separated from
the Gag and Pol proteins, banding predominantly at very
low densities (Figure 1C-F, lower panels). Interestingly,
gp80
SU and gp18
LP proteins showed a different density
distribution (Figure 1E+F, lower panels), which might sug-
gest that they are found not in a detergent-resistant pro-
tein complex in the viral particle.
Taken together, these results suggest that particle-
associated PFV Pol exists predominantly as mature
p85
PR-RT and p40
IN subunits. Furthermore, Pol p127
Pol
precursor protein, frequently observed in crude particle
preparations, reflects mainly copurified extra-particlular
Pol aggregates not enveloped by a lipid membrane.
Therefore, a reliable statement on PFV Pol particle-
association in crude virion preparations necessitates a
subtilisin digestion prior to particle lysis and subsequent
protein composition analysis as performed for the char-
acterization of virions generated from Gag-Pol fusion
protein mutants shown below.
Cellular expression pattern of PFV Gag-Pol fusion
proteins
PFV Pol naturally exists only as a separate Pol protein. To
examine whether expression of an orthoretroviral-like
Gag-Pol fusion protein is compatible with PFV replication,
in particular virion morphogenesis, release and infectivity,
we generated several constructs expressing artificial PFV
Gag-Pol fusion proteins (Figure 2). We created expression
constructs for pure in-frame Gag-Pol fusion proteins, dif-
fering only in their Gag domains and the presence of PFV
PR cleavage sites between the Gag and Pol ORF (GP1,
GP2, GP3 and GP4). In addition, we designed an expres-
sion construct separating PFV Gag and Pol ORF by a
minimal HIV-1 Gag/Pol ribosomal frameshift site (GfP1).
Translation of this construct’s mRNA should result in a
protein mixture, containing full-length PFV Gag with
some additional HIV-1 Gag derived C-terminal amino
acids (aa) and a PFV Gag-Pol fusion protein with an inter-
vening PFV PR cleavage site and some HIV-1 Gag/Pol fra-
meshift site encoded aa, at a ratio as observed for HIV
Gag and Gag-Pol protein expression. For some constructs
variants with catalytically inactive PFV PR (D24Am u t a -
tion) were generated (GP1 iPR, GfP1 iPR) to examine the
particle assembly and release potential of the Gag-Pol
fusion proteins instead of a mixture of precursor protein
and its cleavage products derived from the respective
parental constructs.
First, we analyzed viral protein expression and infec-
tious virus production after transient transfection of
individual proviral expression constructs in 293T cells
(Figure 3). The biochemical analysis of cell lysates
demonstrated similar Gag, Env and Bet expression levels
for the individual constructs (Figure 3A, C, D, E, lane
1-9). Some differences in the reactivity of the gp130
Env
and gp170
Env-Bet precursor proteins to anti-SU and anti-
LP antibodies were noted. The reason for this is cur-
rently unclear. However, preliminary data suggest that
the anti-SU monoclonal antibody does not recognize all
cell-associated PFV Env species equally well (data not
shown). In general, only very low levels of Gag-Pol
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Page 4 of 14fusion precursor proteins were detectable (Figure 3A, B,
lane 3-9). Only for the GP4 protein (PGP4), containing
just the natural RT-IN cleavage site in the Pol coding
sequences, as well as for the GfP1 and GP1 variants
with catalytically inactive PFV PR domains (PGfP1 iPR,
PGP1 iPR), higher fusion protein precursor levels were
observed (Figure 3A, B, lane 4, 6, 9). In contrast, all
fusion constructs with natural or artificial PFV PR clea-
vage sites at the C-terminus of the Gag coding
sequences and active PFV PR domains (PGfP1, PGP1,
PGP2 and PGP3) expressed Gag-specific products at
levels comparable to the authentic proviral expression
c o n s t r u c t( F i g u r e3 A ,l a n e1 ,3 ,5 ,7 ,8 ) .E x p r e s s i o no f
p68
Gag was detectable in samples transfected with pro-
viral constructs PGfP1, PGP1, PGP2 and PGP3, whereas
it was absent in GfP1iPR and GP1iPR expressing cells
(Figure 3A, lane 3-8). Gag precursor p71
Gag was only
generated by expression constructs PGfP1 and PGP1
containing the full-length Gag ORF and C-terminal pro-
cessing sites (Figure 3A, lane 3, 5).
In contrast, Pol expression of some constructs deviated
significantly from wild type. The HIV-1 frameshift site
containing construct PGfP1 and its PR-deficient variant
PGfP1 iPR expressed lower amounts of Pol than the
respective wild type counterparts (wt and iPR) (Figure
3B, lane 1-4). Quite the opposite was observed for most
constructs having Gag and Pol ORFs fused in-frame
(PGP1, PGP2, PGP3) that expressed higher amounts of
Pol (Figure 3B, lane 1, 2, 5-9). Constructs with active PR
domains and natural or artificial cleavage sites N-term-
inal of the Pol encoded sequences (PGfP1, PGP1, PGP2,
PGP3) gave rise to p127
Pol precursor products (Figure
3B, lane 3, 5, 7, 8). For the GfP1 and GP2 Pol precursor
proteins, the molecular weight was slightly increased in
comparison to wild type (Figure 3B, lane 1, 3, 7). This
most likely is due to the N-terminal presence of a HIV-
Gag-Pol sequence or the PFV p3
Gag domain, respectively.
Similar to wild type Pol these fusion proteins showed Pol
precursor processing into p85
PR-RTand p40
IN (Figure 3B,
lane 7, 9, 11, 12). For the PGP4 construct, containing
only the natural Pol PR-RT/IN cleavage site, p40
IN was
observed at levels comparable to the other fusion pro-
teins but no p85
PR-RT was detectable (Figure 3B, lane 9).
Similar results were obtained using corresponding PFV
Gag-Pol fusion protein packaging expression vectors of a
4-component PFV vector system, when transfected into
293T either alone or in combination with the residual
vector system components (data not shown).
Taken together, this analysis revealed that all con-
structs expressed the predicted Gag-Pol fusion proteins,
which were efficiently processed into the expected clea-
vage products. In comparison to wild type, relative cel-
lular Pol expression was reduced when translation was
controlled by a HIV-1 Gag/Pol frameshift site and
increased upon in-frame fusion of PFV Gag and Pol
ORFs.
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Figure 2 Schematic illustration of PFV Gag-Pol expression constructs. Schematic outline of the parental proviral expression construct
pczHSRV2 wt. Below enlargement of the regions of Gag-Pol ORF overlap/fusion in the individual constructs as indicated. Sequences of PFV Gag
origin in dark grey and light grey boxes, of PFV Pol origin in white boxes and of HIV-1 origin in black boxes. Amino acids (aa) are given in the
1-letter code. Aa not originally encoded by either PFV or HIV-1 derived sequences but from cloning sites are in italic. CMV, cytomegalovirus
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Figure 3 Analysis of expression constructs for different Gag-Pol fusion proteins. 293T cells were transiently transfected with the individual
proviral expression constructs (A-E) or Gag/Pol packaging constructs in context of the replication-deficient 4-component PFV vector system (F)
as indicated. Cell lysates (cell, lane 1-10, 1/25 of total) as well as viral particle preparations (virus, lane 11-29, 10 ml supernatant equivalents),
concentrated by ultracentrifugation through 20% sucrose and either digested with subtilisin (+) or mock incubated (-) prior to lysis, were
analyzed by Western blot. Antibodies or antisera used were specific for A) PFV Gag (a-Gag), B) PFV p85
PR-RT and PFV p40
IN (a-RT + a-IN), C) PFV
Env SU (a-SU), D) PFV Env LP (a-LP) E) PFV Bet (a-Bet), F) rabbit GAPDH (a-GAPDH). The identity of the individual proteins is indicated in the
middle, the molecular weight of the protein standard on both sides. 293T cells were transfected with: pczHSRV2 wt (lane 1, 11, 12; wt);
pczHSRV2 iPR (lane 2, 13, 14; iPR); pczHSRV2 PGfP1 (lane 3, 15, 16; PGfP1); pczHSRV2 PGfP1 iPR (lane 4, 17, 18; PGfP1 iPR); pczHSRV2 PGP1 (lane 5,
19, 20; PGP1); pczHSRV2 PGP1 iPR (lane 6, 21, 22; PGP1 iPR); pczHSRV2 PGP2 (lane 7, 23, 24; PGP2); pczHSRV2 PGP3 (lane 8, 25, 26; PGP3);
pczHSRV2 PGP4 (lane 9, 27, 28; PGP4); pcDNA3.1+zeo (lane 10, 29; mock). G) Relative titers of the individual 293T supernatants on BHK/LTR(PFV)
lacZ cells. Means and standard deviations (n = 4) are shown. H) Relative infectivity of extracellular culture supernatants of 293T cells transfected
with Gag/Pol packaging constructs in context of the replication-deficient 4-component PFV vector system using an eGFP marker gene transfer
assay determined 3 days post infection. Means and standard deviations (n = 4-8) are shown. Identical amounts of Gag, Pol and Gag-Pol fusion
protein packaging constructs were used. In case of the Gag-Pol fusion protein packaging constructs the total amount of transfected DNA was
kept constant by the addition of empty pcDNA3.1zeo vector. Cotransfection of empty pcDNA3.1+zeo vector (plain), p6iGag4 (+Gag wt), or
p6iPol (+ Pol wt).
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Analysis of the particle-associated protein composition
revealed significant differences between the individual
constructs (Figure 3, lane 11-28). First, a proviral
expression construct having only the PR inactivated
(iPR) displayed no particle-associated Gag and Pol pro-
cessing (Figure 3A+B, lane 13, 14). However, unlike the
wild type sample the p127
Pol protein of the iPR particle
sample was only partially susceptible to subtilisin diges-
tion (Figure 3B, lane 11, 13). This indicates that encapsi-
dated, subtilisin-resistant Pol precursor is detectable if
further particle-associated processing is prevented.
Second, the reduced cellular expression of Pol by the
PGfP1 constructs resulted in somewhat lower amounts of
particle-associated Pol protein (Figure 3B, lane 3, 15).
However, unlike the wild type Pol precursor, the p127
Pol
precursor protein present in PGfP1 samples was only par-
tially sensitive to subtilisin digestion (Figure 3B, lane 11,
12, 15, 16). A similar phenomenon was observed for most
of the constructs having Gag and Pol ORFs fused in-frame
(PGP1 to 3), although the Pol precursor seemed to be
more sensitive to subtilisin digestion than that of PGfP1
(Figure 3B, lane 15, 16, 19, 20, 23-26). This might point to
a reduced PFV Pol processing capacity of these fusion pro-
teins in comparison to wild type.
PGfP1 iPR, coexpressing p200
Gag-Pol and p71
Gag,a l s o
showed only a partial subtilisin sensitivity of the p200
Gag-
Pol precursor protein present in particle samples (Figure
3B, lane 17, 18). In contrast, the PGP1 iPR and PGP4 con-
structs, expressing only PFV Gag-Pol fusion proteins, con-
tained hardly any subtilisin resistant particle-associated
Gag-Pol fusion precursor proteins (Figure 3A+B, lane 17,
18, 21, 22, 27, 28). This indicates a strong deficiency in
particle release of both constructs, which was further sup-
ported by the strongly reduced amounts of Env proteins
detectable in these samples (Figure 3C+D, lane 21, 22, 27,
28). All other constructs showed capsid release similar to
wild type (Figure 3A, lane 11-20, 23-26). Despite viral PR
domain inactivation several Gag-Pol fusion protein clea-
vage products, but no mature p85
PR-RT or p40
IN subunits,
were detected in the untreated PGP1 iPR particle samples
using the anti-Pol antibody mixture (Figure 3B, lane 22).
These cleavage products most probably represent partially
degraded extraparticular Gag-Pol fusion protein since they
completely disappear upon subtilisin pretreatment.
Taken together these results suggest that uncleaved
Gag-Pol precursor proteins alone are unable to support
efficient particle release, but can be incorporated to some
extent in particulate structures if p71
Gag or p68
Gag is
coexpressed.
Infectivity of PFV Gag-Pol fusion protein mutants
Titration of viral supernatants generated by transient
transfection of the different proviral expression constructs
into 293T cells revealed a 5-, 30- and 200-fold reduced
infectivity for the PGfP1, PGP2 and PGP3 constructs,
respectively (Figure 3G). Only the PGP1 construct dis-
played wild type infectivity. The PGP4 and all constructs
with inactivated PR (PGP1 iPR, PGfP1 iPR, iPR) were non-
infectious. Thus PFV replication is compatible with
orthoretroviral-like Gag-Pol expression strategies as long
as processing between Gag and Pol domains is retained.
A similar picture was obtained when corresponding PFV
Gag-Pol fusion constructs were examined in a replication-
deficient 4-component PFV vector system, although overall
infectivity of constructs with an active PR domain
was somewhat increased in comparison to wild-type
(Figure 3H, black bars), except GP4 that remained non-
infectious. GfP1 derived supernatant showed wild type
level of infectivity whereas those of GP2, GP3, and GP1
were 2-, 3-, and 7-fold increased. As expected all superna-
tant samples of constructs with inactive PR (PP iPR, GfP1
iPR, GP1 iPR) were non-infectious. Cotransfection of an
identical amount of the wild type p71
Gag expression packa-
ging construct led to a 2- to 5-fold decrease of infectivity in
wild type (wt), GfP1, GP1 and GP2 samples. No change
was observed for GP3 or PR inactive supernatants (PP iPR,
GfP1 iPR, GP1 iPR) (Figure 3H, light grey bars). In con-
trast, the non-infectious GP4 construct was partially res-
cued by wild type Gag coexpression to levels of about 25%
of the corresponding wild type sample (wt). Cotransfection
of an identical amount of wild type p127
Pol expressing
packaging construct resulted in no or only minor changes
of infectivities in wild type (wt), GP1, GP2, and GP3 sam-
ples (Figure 3H, dark grey bars). The GfP1 sample was the
only one where wild type p127
Pol coexpression led to a
7-fold increase in supernatant infectivity. Infectivity of non-
infectious samples generated by cotransfection of separate
wild type Gag and Pol iPR expression vectors (PG + PP
iPR) could be rescued to 50% levels of the respective wild
type control (PG + PP). In contrast, GfP1 iPR and GP1 iPR
samples were complemented by wild type p127
Pol coex-
pression to a much lower extent if at all. This suggests that
GP4 has a defect in Gag domains that can be partially res-
cued by wild type Gag. Furthermore, the Gag-Pol precur-
sor fusion proteins with inactive PR domain seem to exert
dominant-negative effects on wild type particle infectivity.
Ultrastructural analysis of orthoretroviral-like Gag-Pol
expression PFVs
Subsequently, an ultrastructural analysis of 293T cells
transfected with individual proviral expression con-
structs was carried out by electron microscopy to exam-
ine the effects of selected mutants on PFV particle
morphogenesis. Representative electron micrographs are
shown in Figure 4.
In cells transfected with the wild type proviral expres-
sion construct predominantly regular shaped capsid
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Figure 4 Ultrastructural analysis of particle morphogenesis of proviruses expressing different Gag-Pol fusion proteins.E l e c t r o n
micrographs showing representative thin sections of transiently transfected 239T cells using different pczHSRV2-derived proviral expression
constructs as indicated. (A, B) wt; (C, D) iPR; (E, F) PGfP1; (G, H, I) PGfP1 iPR, (J, K) PGP1; (L, M) PGP1 iPR; (N, O) PGP4. Magnifications: (A) 15200×,
(B) 31200×, (C) 29000×, (D) 19500×, (E) 14300×, (F, N) 15500×, (G) 23000×, (H) 15400×, (I) 15800×, (J, L, M) 14500×), (K) 13000×, (O) 13300×. Scale
bar: 250 nm.
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as well as budding structures at plasma and intracellular
membranes (Figure 4A, B). In contrast, more heteroge-
neous capsid structures were observed in samples trans-
fected with the proviral expression construct having the
PR inactivated (iPR) (Figure 4C, D). Many of these
adopted a horse shoe-like morphology of apparently
incompletely closed capsid structures, similar as
reported previously for this type of mutation [22,23].
However, capsid structures with apparently normal mor-
phology and budding structures at different cellular
membranes were also detectable.
Cells expressing the PGfP1 proviral expression con-
struct produced capsid structures and viral particles that
closely resembled that of wild type (Figure 4E, F). In
contrast, transfection of the PGfP1 iPR proviral con-
struct, expressing p71
Gag and p200
Gag-Pol, resulted in the
appearance of very aberrant capsid structures at intra-
cellular locations, but also membranous regions of the
cell (Figure 4G, H, I). Their size and shape displayed a
very broad heterogeneity and many incompletely closed
capsid structures were observed. The morphogenic phe-
notype of the iPR mutation in the context of the riboso-
mal frameshift-mediated Gag-Pol fusion protein
generated by PGfP1 (PGfP1 iPR mutant) was definitely
more pronounced in comparison to the wild type trans-
lational scenario with Pol expressed as an independent
protein (iPR mutant) (compare Figure 4C, D to Figure
4G, H, I).
Capsids and virions derived from the PGP1 expression
construct were nearly identical to wild type (Figure 4J,
K). However, if PGP1 was combined with the iPR muta-
tion resulting in PGP1 iPR, which expresses only the
p200
Gag-Pol protein, no structures with any similarity to
original PFV capsids were detectable (Figure 4L, M). In
contrast, electron-dense aggregated structures were
observed at intracellular locations including the centro-
some that might represent aggregated Gag-Pol fusion
proteins. Similarly, in samples transfected with the non-
infectious PGP4 proviral expression construct no regular
PFV capsid structures or budding particles were detect-
able (Figure 4N, O). Here too, aberrant intracellular
structures that might be aggregated PFV structure pro-
teins were found. The electron-dense aggregated struc-
tures, most probably containing Gag-Pol fusion proteins,
were only detected in these latter two samples and
never observed in any other samples.
These results strongly suggest that PFV Gag-Pol
fusion proteins alone are incapable of assembly into reg-
ular shaped capsid structures.
Discussion
PFV polymerase biosynthesis and encapsidation are
unique amongst retroviruses [reviewed in [1]]. First, Pol
is expressed as a separate p127
Pol precursor protein
[24-27]. Second, only the precursor but not the mature
subunits p85
PR-RTand p40
IN is encapsidated into the vir-
ion in a viral RNA genome-dependent manner that
might involve additional Gag-Pol protein interactions
[12,13,16,20,21,28].
During the characterization of PFV Gag/Pol constructs
resulting in an orthoretroviral-like expression strategy in
this study, we made an unexpected observation. In control
particle lysates from cells transfected only with a PFV Pol
expression construct the p127
Pol precursor protein was
detectable, which was pelletable like intact PFV particles
through 20% sucrose. However, this pelletable PFV p127
Pol
seemed not to be enveloped by a lipid membrane, because
it was sensitive to digestion by subtilisin, a non-membrane
permeable endoprotease. Similarly, large amounts of pre-
dominantly subtilisin-sensitive p127
Pol precursor were
detectable in partially purified PFV wild type virions from
different sources, as reported previously [13,16,20,21].
In contrast, the mature p85
PR-RTand p40
IN subunits in the
same samples were mainly protected against subtilisin
digestion. Furthermore, the amounts of Gag and Env pro-
cessing products as well as p85
PR-RTand p40
IN subunits,
but not of p127
Pol precursor correlated with viral infectivity
in fractions of linear velocity sedimentation gradient centri-
fugation runs that were used to further purify PFV parti-
cles. Together this strongly suggests that the majority of
p127
Pol precursor detectable in the supernatant of PFV
i n f e c t e dc e l l si sn o tp a rticle-associated.
The release mechanism of this non-particle-associated
p127
Pol is currently unclear because it does not contain
any classical signal peptide sequence potentially target-
ing it to the secretory pathway. Interestingly, only non-
particle-associated p127
Pol was detectable in supernatant
pellets from cells expressing PFV Pol alone, although
intracellularly p85
PR-RTand p40
IN cleavage products
were observed. One explanation for this might be the
failure of potentially co-released mature Pol subunits or
mature Pol subunits derived from secreted p127
Pol pre-
cursor protein to be pelleted through 20% sucrose.
Alternatively, indeed only the p127
Pol precursor is
released, and its further processing is prevented. Poten-
tial reasons for such a processing defect could be a mis-
folding of the released p127
Pol precursor resulting in a
lack of PFV Pol proteolytic activity mediated by oligo-
merization through the IN domain as recently proposed
[29], a lack of essential cofactors (e.g. the recently
described regulatory PARM viral genomic sequence ele-
ment [18]), or a direct inhibition of PFV PR activity by
factors of the extracellular environment. However, the
observation that non-particle-associated, pelletable PFV
Pol retains its RT activity [[16], and data not shown] at
least seems to exclude a gross misfolding of the protein
destroying all its enzymatic functions.
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and not as the naturally translated Gag-Pol fusion protein
was reported to result in assembly and release of infectious
virions with particle associated Pol [9,10]. This indicates
that orthoretroviral Pol can be packaged into capsids inde-
pendent of the natural Gag-Pol fusion protein interaction
with the Gag protein, although at reduced efficiency
[9,10]. In contrast to our results, secreted pelletable Pol
precursor or mature subunits were not observed upon
orthoretroviral Pol expression as a separate protein [9,10].
Only Park et al. [7] described the release of HIV-1 Gag
p24 and RT in the absence of detectable particle formation
for cells transfected with proviral HIV-1 constructs
expressing only in-frame Gag-Pol fusion protein and no
separate Gag protein. Though, unlike non-particle asso-
ciated PFV Pol, which can be pelleted by ultracentrifuga-
tion through sucrose, this was not possible for the HIV-1
Gag p24 and RT protein detectable in supernatants from
cells transfected with this mutant proviral HIV-1 expres-
sion construct [7].
The observation of apparent extraparticle p127
Pol pre-
cursor protein detectable in pelleted PFV particle pre-
parations is still in line with the current model of PFV
Pol incorporation exclusively at its precursor state. How-
ever, it suggests that during or early after packaging effi-
cient Pol precursor processing occurs, resulting in
particle-associated PFV Pol predominantly as mature
p85
PR-RTand p40
IN subunits. If this is true then inhibition
of further subunit processing after particle incorporation
should result in the clear detection of particle-associated
Pol precursor. Consistent with this is our observation of
larger amounts of subtilisin-resistant p127
Pol precursor in
crude virion preparations generated by constructs har-
boring a catalytically inactivated PFV PR domain (iPR).
The detection of large amounts of non-particle asso-
ciated Pol precursor in crude PFV particle preparations
of different origin represents another special feature of
F V s .F u r t h e r m o r e ,t h e s ed a t ai n d i c a t et h a to n l ym a t u r e
PFV Pol p85
PR-RTand p40
IN subunits are a good measure
for particle-associated Pol in wild type PFV particle pre-
parations. However, the results of the iPR mutants show
that viral particles of mutants with a reduced or abol-
ished proteolytic activity might harbor particle-associated
Pol precursor, which can only be distinguished reliably
from its non-particle associated counterpart by subtilisin
digestion prior to particle lysis. This is an important
aspect for the analysis of the different PFV Gag-Pol
fusion construct of this study discussed below in greater
detail, since the results from subtilisin analysis suggest
that some of them display a reduced precursor proces-
sing capacity, which would have not been detected using
standard virion protein composition analysis.
The characterization and analysis of expression con-
structs for different PFV Gag-Pol fusion proteins in this
study revealed several interesting features of PFV. First,
we demonstrate that PFV Pol expression in an orthore-
troviral-like Gag-Pol fusion manner, even exclusively as
in-frame Gag-Pol fusion, is compatible with PFV replica-
tion, which is true as long as proteolytic processing
between Gag and Pol domains is possible. This is differ-
ent to orthoretroviruses. Here in-frame Gag-Pol fusion
expression in the absence of Gag coexpression is incom-
patible with viral replication [4,5,7,8]. In case of murine
leukemia virus (MLV) and Rous sarcoma virus (RSV)
in-frame Gag-Pol fusions abolish precursor processing,
virion assembly and particle release [4,5]. On the con-
trary, spleen necrosis virus (SNV) and HIV-1 in-frame
Gag-Pol fusion expression results in normal or enhanced
structural protein expression associated with the failure
to assemble and release infectious virions [7,8]. Thus
PFV tolerates a much larger variation in the Gag to Pol
ratio as orthoretroviruses do and processing by the viral
PR is not abolished in a Gag-Pol fusion protein context.
T h i sm i g h tb ear e s u l to ft h eu n i q u eP F VP o lp a c k a g i n g
strategy with viral genomic RNA serving as a bridge
between both components during capsid assembly, which
might be a limiting factor determining the level of Pol
incorporation. In line with this is the observation that all
in-frame PFV Gag-Pol fusions, similar as reported for
analogous orthoretroviral constructs [4,5,7,8], led to
higher relative cellular Pol ex p r e s s i o ni nc o m p a r i s o nt o
authentic PFV Pol translation from a separately spliced
RNA. However, the levels of particle-associated mature
p85
PR-RTand p40
IN of a full-length, cleavable in-frame
PFV Gag-Pol expression (PGP1) were comparable to wild
type and this correlated with infectivity. In contrast, ribo-
somal-frameshift mediated expression of PFV Gag-Pol
resulted in lower cellular Pol levels compared to wild
type. The infectivity of particles derived from HIV-1 fra-
meshift site mediated Gag-Pol expression (GfP1) was
reduced 5-fold and was reflected by reduced Pol particle
incorporation and Gag precursor processing. Thus an
optimal particle-associated PFV Gag to Pol ratio is
important for maximal virion infectivity and might be
regulated in part by interaction of PFV Pol with the viral
RNA during capsid incorporation. Therefore increased
cellular Pol precursor levels are not detrimental for PFV
particle morphogenesis.
Second, there were significant differences of the var-
ious in-frame PFV Gag-Pol fusion constructs examined
in the level of compatibility with viral replication. The
in-frame GP2 and GP3 mutants displayed a similar Pol
incorporation as GP1 but infectivity was reduced 30-
and 160-fold respectively. This can be best explained by
the failure of both mutants to generate p71
Gag in addi-
tion to p68
Gag.I nt h ec a s eo fG P 2 ,t h ep 3
Gag domain is
fused to the N-terminus of Pol and cannot be removed
due to the absence of a PFV PR cleavage site whereas
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Gag coding sequence
removed. Therefore, both constructs lead only to p68
Gag
expression after fusion protein processing. It has been
demonstrated previously that PFV particles composed
exclusively of p68
Gag display a 100-fold reduced infectiv-
ity although particle release and morphology are indis-
tinguishable from wild type [30,31]. The infectivity levels
of GP2 and GP3 are in a similar range as reported for
PFV particles solely composed of p68
Gag. Interestingly, a
proviral construct similar to GP3 has been described
previously by Löchelt et al. when elucidating the Pol
biosynthesis mechanism [27]. Similar to our results they
reported a 100-fold reduced infectivity of PFV Gag-Pol
in frame fusion within the p3
Gag coding regions. How-
ever, although the authors observed Gag-Pol fusion pro-
tein processing, Pol subunit processing was severely
impaired. This is different to the phenotype of GP3. The
reason for this is currently unclear.
T h ep h e n o t y p eo ft h ei n - f r a m eG P 4f u s i o nc o n s t r u c t
was special since it was the only one examined in the
proviral and vector system context that did not allow
production of infectious PFV particles. The only differ-
ence between GP4 and GP3 is the absence of a functional
p68
Gag/p3
Gag cleavage site between the fused Gag and Pol
ORFs. Therefore GP4 only contains the natural Pol PR-
RT/IN processing site. This leads to fusion protein pro-
cessing into mature p68
Gag-p85
PR-RTand p40
IN subunits,
indicating that also PFV PR is still active with a large N-
terminal protein fusion. However, neither the GP4 pre-
cursor nor the mature subunits are able to support
release of infectious PFV virions. This is demonstrated by
the absence of significant amounts of subtilisin resistant
structural proteins in respective particle preparations and
the failure to detect normal capsid structures upon ultra-
structural analysis of cells expressing GP4. Interestingly,
coexpression of wild type Gag but not Pol resulted in a
partial rescue of viral infectivity. In this setting the essen-
tial viral enzymatic functions are provided by the GP4
protein. Therefore, this suggests that coexpressed wild
type Gag and GP4 can interact, probably through their
Gag domains, and generate particles that retain some
infectivity. Thus GP4 seems to have a defect in capsid
assembly involving its Gag domains presumably due to
C-terminal addition of the large p85
PR-RTPol domain.
Inactivation of the PFV Pol PR domain always resulted
in the failure to produce infectious particles. However, it
had different effects on particle formation and release
depending on the context of the expression construct. PR
inactivation in the PFV wild type (iPR) or GfP1 context
(GfP iPR), where wild type p71
Gag is coexpressed, allowed
formation and release of subtilisin resistant capsid struc-
tures that contained significant amounts of Pol precursor
respectively GfP1 precursor fusion protein. Though the
capsid morphology of both types of virions was aberrant,
it was more pronounced for the GfP1 construct. In con-
trast, GP1 iPR failed to support capsid assembly and
release of significant amounts of subtilisin resistant cap-
sids. These results suggest that similar to reports for
orthoretroviruses PFV Gag-Pol fusion proteins alone are
unable to support correct capsid assembly and release
[5,7,8]. However, like orthoretroviruses coexpression of
Gag can rescue the particle release defect [8].
Conclusions
Taken together our study describes for the first time the
release of significant amounts of non-particle associated,
pelletable PFV Pol protein, that appear to have no proteo-
lytic, but polymerase, activity. However, the mechanism of
Pol secretion remains unclear. Furthermore, we demon-
strate that PFV Pol translation in an orthoretroviral-like
manner by a lentiviral frameshift mechanism or solely as
an in-frame Gag-Pol fusion protein is compatible with
viral replication as long as processing between Gag and
Pol domains is retained. Finally, PFV seems to tolerate
much larger variations in the Gag to Pol ratio than orthor-
etroviruses, presumably as a result of the unique Pol cap-
sid incorporation strategy with viral RNA serving as a
bridging molecule between both proteins.
Methods
Cells
The human kidney cell line 293T [32], the human fibro-
sarcoma cell line HT1080 [33], and the PFV indicator
cell line BHK/LTR(HFV)lacZ [34] were cultivated in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal calf serum and
antibiotics. G418 was added at a final concentration of 1
mg/ml to BHK/LTR(HFV)lacZ cells.
Expression constructs
A schematic outline of the constructs used in this study
i ss h o w ni nF i g u r e2 .I nt h ee n l a r g e m e n to ft h eG a g - P o l
ORF overlap/fusion of the individual constructs the
amino-acid sequence is given. All constructs are based
on authentic, non-codon-optimized PFV ORFs. The 4-
component PFV vector system consisting of the PFV Gag
expression vector pcziPG4 (PG), the PFV Pol expression
vector pcziPol (PP), the PFV Env expression construct
pczHFVenvEM002 (PE), and the enhanced green fluores-
cent protein (EGFP) expressing PFV transfer vector
pMD9 (PV), has been described previously [28]. In this
study a variant transfer vector puc2MD9 [35] and modi-
fied PFV Gag (p6iGag4) and PFV Pol (p6iPol2) expres-
sion constructs were used, all containing a pUC19
backbone instead of the original pcDNA3.1 zeo back-
bone. Expression vectors for PFV Gag-Pol fusion proteins
all based on the p6iGag4 construct were generated by
removing the start methionine in PFV Pol and fusing the
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positions resulting in constructs GP1, GfP1, GP2, GP3
and GP4 as illustrated in Figure 2. In addition, the
authentic Pol translation initiation codon in the 3’ part of
the Gag ORF naturally overlapping with the PFV Pol
ORF had been inactivated without changing the Gag pro-
tein sequence. Further modifications of the individual
constructs are the insertion of a second p68/p3 proteoly-
tic cleavage site between the PFV Gag- and Pol-ORF
fusion in GP1 and GfP1. GfP1 harbors in addition a mini-
mal HIV-1 Gag-Pol frameshift element containing an
HIV-1 NC/p1 PR cleavage site [36]. In GP2, PFV Gag
and Pol ORFs are fused in-frame without any additional
sequences. GP3 has most of the PFV Gag p3 domain
removed leaving the natural p68/p3 cleavage site intact
whereas in GP4 the PFV Gag p3 domain was completely
removed by fusing PFV Pol to p68
Gag coding sequences.
For some experiments, expression vectors for Gag-Pol
fusion proteins with a catalytically inactive PR (GP1iPR
and GfP1iPR) containing a Pol D24A mutation [23,37]
were used as indicated. The amino acid sequences in sin-
gle letter code of the Gag-Pol fusion regions of the differ-
ent mutants, starting with the non-altered aa position
PFV Gag G613 and terminating with PFV Pol L9,a r e
shown in Figure 2. Expression constructs for the Gag-Pol
fusion proteins were generated by standard PCR cloning
techniques and were verified by sequencing analysis.
Further details on the cloning procedures and mutagen-
esis primers used are available upon request. The differ-
ent PFV proviral Gag-Pol fusion constructs depicted
were generated by replacing a 1829 bp SwaI/PacIf r a g -
ment of the infectious molecular clone pczHSVR2 [38]
with the corresponding fragment of eukaryotic constructs
expressing only the mutant Gag-Pol fusion proteins.
Proviral constructs are labeled with the prefix “P” (e.g.
PGP-1) that is omitted in Gag/Pol packaging constructs
of the replication-deficient 4-component PFV vector
system (e.g. GP-1).
Transfections and particle concentration
PFV supernatants containing recombinant viral particles
were generated as described earlier [39,40]. Briefly, replica-
tion-competent PFV supernatants were generated by
transfection of proviral expression constructs into 293T
cells as indicated using Polyethyleneimine (Aldrich) (16 μg
total DNA per 10 cm dish) or Polyfect (Qiagen) transfec-
tion reagents (3 μg total DNA per well in 12-well plates).
Replication-deficient PFV vector supernatants were pro-
duced by cotransfection of 293T cells with equal amounts
of puc2MD9, pczHFVenvEM002, p6iPol and p6iGag4 or
mutants thereof as indicated. Twenty-four hours post-
transfection sodium butyrate (10 mM final concentration)
was added to the growth medium for 8 h. Subsequently,
the medium was replaced and harvested an additional
16-18 h later by passing it through a 0.45 μm syringe filter
to obtain cell free culture supernatant (5 ml per 10 cm
dish or 1.5 ml per well of 12-well plates) used for infection
or particle purification. For particle concentration, extra-
cellular viral particles were harvested by ultracentrifuga-
tion through a 20% sucrose cushion in SW28 rotors
(Beckman) for 3 h at 25.000 rpm (112,000 g) and 4°C.
After discarding the supernatant the particulate material
was gently resuspended in phosphate-buffered saline
(PBS) and further processed as indicated. For Western
blot analysis an equal amount of 2× sodium dodecylsulfate
protein sample buffer was added.
Subtilisin treatment
Subtilisin treatment of concentrated particles was per-
formed as described previously [41]. Briefly, for subtilisin
treatment half of the particulate material resuspended
in PBS was incubated for 2 h at 37°C in digestion mix
containing final concentrations of 1 mM CaCl2,5 0m M
Tris-HCl pH 8.0 and subtilisin (25 μg/ml). The other half
was treated as a mock control by omitting subtilisin in the
digestion mix. The digestion was stopped by adding Phe-
nylmethylsulfonylfluorid (PMSF) at a final concentration
of 100 μg/ml to the reaction mixture. For analysis of pro-
tein composition, an equal amount of 2× sodium dodecyl
protein sample buffer was added to each reaction and the
samples were separated by SDS gel electrophoresis and
analyzed by Western blotting.
Linear velocity sedimentation gradient centrifugation
After initial particle concentration by centrifugation
through sucrose, described above, pelleted particulate
material from forty-two 10 cm dishes (210 ml supernatant)
resuspended in PBS, with or without prior subtilisin diges-
tion, was carefully overlaid onto an 1.8 ml iodixanol (Opti-
Prep
®) gradient in PBS containing of 200 μl layers ranging
from 15% to 40%. In some experiments the gradient con-
tained NP40 at a final concentration of 1% (v/v). Following
ultracentrifugation at 48,000 rpm (197,000 g) and 4°C
for 3 h (TLS55 rotor; Beckman) 120 μl fractions were
collected from the top to the bottom. Subsequently, the
infectivity of the fractions was determined by flow cytome-
try- or histochemistry-based assays, as well as the protein
composition examined by Western blot analysis.
Antisera, western blot expression analysis and
quantification of particle release
Western blot expression analysis of cell- and particle-
associated viral proteins was performed as described pre-
viously [37]. Polyclonal antisera specific for full-length
PFV Gag [41], full-length PFV Bet or the leader peptide
(LP) of PFV Env, aa 1-86 [37] were used. Furthermore,
hybridoma supernatants specific for PFV reverse tran-
scriptase (RT) (clone 15E10), PFV Integrase (IN) (clone
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P3E10) [42-44] were employed in some experiments. For
loading controls commercially available polyclonal rab-
bit-anti mouse GAPDH (Sigma G9545) or monoclonal
mouse-anti rabbit GAPDH antibodies (Sigma G8795)
were used. After incubation with secondary anti-rabbit or
anti-mouse antisera the blots were developed using
Immobilion™ Western (Millipore) reagent. The chemilu-
minescence signal was digitally recorded using a LAS-
3000 imager (Fujifilm) and analyzed using the Image
Gauge software package (Fujifilm).
Transductions
For analysis of particle preparations derived from pro-
viral expression constructs BHK/LTR(PFV)lacZ cells
were seeded 24 h prior to transduction with a density of
2×1 0
4/ml in 12 well tissue plates and transduced with
1 ml of viral supernatant or dilutions thereof. After 48 h
the amount of focus forming units (ffu) per ml was
determined by a blue cell assay involving histochemical
b-galactosidase staining [34]. All titration experiments
were performed at least three times and the values in
each independent experiment obtained with the wild
type (wt) proviral expression construct pczHSRV2 were
arbitrarily set to 100%. The titers of pczHSRV2 wt were
in the range between 2-40 × 10
6 ffu/ml.
For analysis of replication-deficient FV vector-derived
particle preparations, HT1080 cells were seeded 24 h
prior to transduction at a density of 2 × 10
4/ml in 12 well
tissue plates and transduced with 1 ml of viral superna-
tant or dilutions thereof. The fraction of EGFP expressing
cells was determined by flow cytometry analysis 72 h
after transduction [28]. All transduction experiments
were performed at least three times, and in each indepen-
dent experiment the values obtained with wild type
p6iGag4 and p6iPol2 constructs were arbitrarily set to
100%.
Electron microscopy analysis
At 48 h post transfection, 293T cells were harvested and
processed for electron microscopy analysis as described
previously [45].
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